Description
CD80 (human):Fc (human) (rec.) | CHI-HF-210CD80-C100
CD80 (B7-1) and CD86 (B7-2) together with their receptors CD28 and CTLA-4 constitute one of the dominant costimulatory pathways that regulate T cell and B cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up-regulated through interferon-γ. B7-1 and B7-2 are both members of the immunoglobulin superfamily. It has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites.
Sequence |
The extracellular domain of human CD80 (aa 35-242) is fused to the N-terminus of the Fc region of human IgG1. |
---|---|
Crossreactivity | Human |
Purity | ≥98% (SDS-PAGE) |
Endotoxin Content | <0.06EU/μg protein (LAL test; Lonza). |
Reconstitution | Reconstitute with 100 µl sterile water. Add 1X PBS to the desired protein concentration. |
Formulation | Lyophilized from 0.2μm-filtered solution in PBS. |
Protein Negative Control |
Fc (human) IgG1 Control (rec.) |
Other Product Data |
NCBI reference NP_005182.1: CD80 (human) |
Declaration | Manufactured by Chimerigen. |